Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nogapendekin alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nogapendekin alfa overview
nogapendekin alfa (ALT-803) is under development for the treatment of relapsed or refractory multiple myeloma, gastroesophageal (GE) junction carcinomas, metastatic castration resistant prostate cancer, hematological tumor such as acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) lymphoma, chronic lymphocytic leukemia (CLL), small cell lung cancer, urothelial carcinoma, Merkle cell carcinoma, gastric cancer, cervical cancer, hepatocellular carcinoma, small lymphocytic lymphoma or lymphoplasmacytic lymphoma, chronic myelogenous leukemia (CML), hereditary nonpolyposis colon cancer, non-small cell lung cancer, squamous non-small cell lung carcinoma, renal cell carcinoma, squamous cell head and neck carcinoma, metastatic melanoma, pancreatic cancer, relapsed or refractory non-Hodgkin lymphoma, primary peritoneal cancer, ovarian cancer, fallopian tube cancer and HIV infections, the relapse of hematologic malignancies after ASCT and coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ALT-803 is administered through parenteral, intravesical, intravenous, intraperitoneal and subcutaneous route. It acts by targeting IL2RG and IL2RB. It was under development for relapsed or refractory acute myelocytic leukemia. It was also under development for non-muscle invasive bladder cancer, B-cell non-Hodgkin lymphoma, follicular lymphoma, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), marginal zone B-cell lymphoma.
ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.
For a complete picture of Nogapendekin alfa’s drug-specific PTSR and LoA scores, buy the report here.